Absci (ABSI) Net Cash Flow (2020 - 2026)
Absci (ABSI) posted Net Cash Flow of -$11.4 million for Q1 2026, down 96.6% sequentially from -$5.8 million in Q4 2025, and down 292.67% YoY from $5.9 million in Q1 2025.
Analysis
Absci (ABSI) Net Cash Flow (2020 - 2026) Analysis & Trends
Absci has reported Net Cash Flow for 7 years, with the latest figure at -$11.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 292.67% year-over-year to -$11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.4 million (down 346.86% YoY) and the FY2025 annual result came in at -$37.1 million, down 18.07% from the prior year.
- Net Cash Flow slipped to -$11.4 million in Q1 2026 per ABSI's latest filing, from -$5.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $49.7 million in Q2 2023 and troughed at -$98.7 million in Q3 2022.
- A 5-year average of -$15.9 million and a median of -$11.4 million in 2026 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 277.63% in 2023, then plunged 422.74% in 2025.
- Over 5 years, Net Cash Flow stood at -$47.4 million in 2022, then soared by 105.92% to $2.8 million in 2023, then grew by 9.43% to $3.1 million in 2024, then tumbled by 289.0% to -$5.8 million in 2025, then sank by 96.6% to -$11.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$11.4 million, -$5.8 million, and -$28.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 99.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.23 Mn |
| Mar 31, 2026 | -11.39 Mn |
| Dec 31, 2025 | -5.79 Mn |
| Sep 30, 2025 | -28.42 Mn |
| Jun 30, 2025 | -8.84 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | -5.44 Mn |
| Jun 30, 2024 | -15.72 Mn |
| Mar 31, 2024 | -13.36 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 8.85 Mn |
| Jun 30, 2023 | 49.70 Mn |
| Mar 31, 2023 | -48.52 Mn |
| Dec 31, 2022 | -47.35 Mn |
| Sep 30, 2022 | -98.69 Mn |
| Jun 30, 2022 | -27.98 Mn |
| Mar 31, 2022 | -29.06 Mn |
| Dec 31, 2021 | -26.69 Mn |
| Sep 30, 2021 | 179.82 Mn |